The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Shikh E.V.

Kafedra klinicheskoĭ farmakologii i propedevtiki vnutrennikh bolezneĭ GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova"

Rebrova E.V.

Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Faculty of Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia, 119991

Ryazanova A.Yu.

Russian Clinical and Research Center of Gerontology, Moscow, Russia, 129226 ,Department of Clinical Pharmacology and Intensive Therapy with the course of clinical pharmacology of CVF, clinical allergology of the Volgograd State Medical University, Volgograd, Russia, 400131

Pereverzev A.P.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Drug-induced hearing loss as a manifestation of drug-induced ototoxicity

Authors:

Ostroumova O.D., Shikh E.V., Rebrova E.V., Ryazanova A.Yu., Pereverzev A.P.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2019;84(4): 72‑80

Read: 30837 times


To cite this article:

Ostroumova OD, Shikh EV, Rebrova EV, Ryazanova AYu, Pereverzev AP. Drug-induced hearing loss as a manifestation of drug-induced ototoxicity. Russian Bulletin of Otorhinolaryngology. 2019;84(4):72‑80. (In Russ.)
https://doi.org/10.17116/otorino20198404172

Recommended articles:
The algo­rithm for clinical and audiological obse­rvation of children born preterm. Russian Bulletin of Otorhinolaryngology. 2025;(1):20-28
Ototoxicity caused by anti-epileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):14-19

References:

  1. Bauman N. Drugs and tinnitus: put yourself in the driver’s seat. Tinnitus Today. 2009;34(1):21-23.
  2. Heck WE, Corwin Hinshaw H, Parsons HG. Auditory Ototoxicity in Tuberculosis Patients Treated with Dihydrostreptomycin. A Report of the Incidence of Hearing Loss in a Series of 1.150 Cases. JAMA. 1963;186:18-20.
  3. Jung TT, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, nonsteroidal antiinflammatory drugs, and quinine. Otolaryngol Clin North Am. 1993;26:791-810.
  4. Johnson AC, Morata T. Occupational Exposure to Chemicals and Hearing Impairment. Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals. 2010;44(4):1-190.
  5. Schellack N, Naude A. An overview of pharmacotherapy-induced ototoxicity. S Afr Fam Pract. 2012;55(4):357-365.
  6. Ototoxicity. Vestibular Disorders Association website. http://www.vestibular.org/ototoxicity. Accessed March 23, 2014.
  7. https://www.drugs.com
  8. Zarandy M. Diseases of the Inner Ear. Springer-Verlag Berlin Heidelberg. 2010;85-89.
  9. Stach BA. Clinical audiology: an introduction. Delmar: Singular Publishing Group; 1998.
  10. Steyger PS. Mechanisms involved in ototoxicity. Seminars in Hearing/Volume. 2011;32(3):217-228. https://doi.org/10.1055/s-0031-1286616
  11. ASHA. (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 2004;36(12):11-19. Ototoxic drugs can damage hearing. Retrieved July 5, 2005, from www.asha.org/about/news/tipsheets/ototoxic
  12. Miller ML. Drug-Induced Diseases. Prevention, Detection, and Management 3rd Edition by James E. Tisdale and Dougglas A. Miller. Chapter 55. Ototoxicity. 2018;1233-1252.
  13. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596. https://doi.org/10.1200/JCO.2004.00.5355
  14. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355-360.
  15. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol. 2017;274(3):1187-1196. https://doi.org/10.1007/s00405-016-4117-z
  16. Ivanov SA, Zhuravskiy SG, Galagudza MM. Tsisplastinovaya ototoksichnost’. Vestnik otorinolaringologii. 2012;4:82-87. (In Russ.)
  17. Mironovich OL, Bliznets YeA, Garbaruk YeS, Belogurova MB, Subora NV, Varfolomeyeva SR, Kachanov DYu, Shamanskaya TV, Markova TG, Polyakov AV. Analiz assotsiatsii polimorfnykh variantov genov TPMT, COMT I ABCC3 s razvitiyem narusheniya slukha, indutsirovannogo priyomom tsisplastina. Vestnik otorinolaringologii. 2018;83(4):60-66. (In Russ.) https://doi.org/10.17116/otorino201883460
  18. Petersen L, Rogers C. Aminoglycoside-induced hearing deficits — a review of cochlear ototoxicity. 2014;77-82. https://doi.org/10.1080/20786190.2014.1002220
  19. American Speech-Language-Hearing Association. Audiologic management of Individuals Receiving Cochleotoxic Drug Therapy. 1994.
  20. Al-Malky G, Suri R, Dawson SJ, et al. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol. 2011;50(2):112-122. https://doi.org/10.3109/14992027.2010.524253
  21. Ramma L, Ibekwe TS. Cochleo-vestibular clinical findings among drug resistant tuberculosis patients on therapy-a pilot study. Int Arch Med. 2012;5(1):1-5. https://doi.org/10.1186/1755-7682-5-3.
  22. Hotz M, Harris F, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope. 1994;104:1130-1134. https://doi.org/10.1288/00005537-199409000-00014
  23. Saunders JE. Vestibuiotoxicity: a risk of home aminoglycoside therapy. J Okla State Med Assoc. 2005;98(12):596-600.
  24. Bezopasnost’ lekarstv. Rukovodstvo po farmakonadzoru. Pod red. Viktorova A.P., Mal’tseva V.I., Belousova Yu.B. K.: Morion; 2007. (In Russ.)
  25. Ratsional’naya antimikrobnaya terapiya. Pod red. Yakovleva V.P., Yakovleva S.V. M.: Litterra; 2003. (In Russ.)
  26. Konyayeva EI, Matveev AV, Radzivill PN, Zakharova AN, Koval EA. Analiz pobochnykh reaktsiy lekarstvennykh sredstv u patsiyentov pozhilogo vozrasta v AR Krym. Krymskiy zhurnal eksperimental’noy i klinicheskoy meditsiny. 2011;2:29-33. (In Russ.)
  27. Kucers A, Bennett N. The use of antibiotics: a comprehensive review with clinical emphasis. London: William Heinemann Medical Books; 1987.
  28. Voogt G, Schoeman H. Ototoxicity of aminoglycoside drugs in tuberculosis treatment. S Afr J Commun Disord. 1996;43:3-6.
  29. Schacht J. Aminoglycoside antibiotics. In: Campbell K.C.M., editor. Pharmacology and ototoxicity for audiologists. New York, NY: Thomson Delmar Learning. 2007.
  30. Troost BT, Waller MA. Drug induced vestibulocochlear toxicity. In: Biller J, editor. Iatrogenic neurology. Boston, MA: Butterworth-Heinemann; 1998.
  31. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs. 1999;58:633-661. https://doi.org/10.2165/00003495-199958040-00005
  32. Bryukhanov VM. Ob ototoksichnosti petlevykh diuretikov. Nefrologiya. 2011;2:13-19. (In Russ.)
  33. Rybak LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993;26:829-844.
  34. Ding D, Liu H, Qi W, Jiang H, Li Y, Wu X, Sun H, Gross K, Salvi R. Ototoxic effects and mechanisms of loop diuretics. Journal of Otology. 2016;11(4):145-156. https://doi.org/10.1016/j.joto.2016.10.001
  35. Mukherjee DK, Mukherjee K. Ototoxicity of commonly used pharmaceutical preparations. Niger Med J. 1979;9:52-57.
  36. Obasikene G, PROC Adobamen, Okundia P, Ogusi FO. Prevalence of ototoxicity in University of Benin Teaching Hospital, Benin city: A 5-year review Year. Nigerian Journal of Clinical Practice. 2012;15(4):453-457.
  37. Balfour AJ. The bite of Jesuits’ bark. Aviat Space Environ Med. 1989;60:4-5.
  38. Lee CS, Heinrich J, Jung TT. Quinine-indued ototoxicity: Alterations in cochlear blood flow. Otolaryngol Head Neck Surg. 1992;107:233.
  39. Cuffel C, Guyot JP. Aspirin ototoxicity: a rare situation today. Rev Med Suisse. 2013;9(400):1785-1788.
  40. Mongan E, Kelly P, Nies K, Porter WW, Paulus HE. Tinnitus as an indication of therapeutic serum salicylate levels. Journal of the American Medical Association. 1973;226:142-145.
  41. Okuyucu S, Guven OE, Akoglu E, Uçar E, Dagli S. Effect of phosphodiesterase-5 inhibitors on hearing. J Laryngol Otol. 2009;123(7):718-722. https://doi.org/10.1017/S002221510900423X
  42. McGwin GJr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Arch Otolaryngol Head Neck Surg. 2010;136(5):488-492. https://doi.org/10.1001/archoto.2010.51
  43. Khan AS, Sheikh Z, Khan S, Dvivedi R, et al. Viagra deafness-sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011;121(5):1049-1054. https://doi.org/10.1002/lary.21450
  44. Barreto MA, Bahmad FJr. Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss. Braz J Otorhinolaryngol. 2013;79(6):727-733. https://doi.org/10.5935/1808-8694.20130133
  45. Caldas N, Caldas SN. Surdez Súbita. Em: Lopes OF, Campos CA. Tratado de Otorrinolaringologia. São Paulo: Roca; 1994.
  46. Maia RA, Cahali S. Surdez súbita. Rev Bras Otorrinolaringol. 2004;70(2):238-248. https://doi.org/10.1590/S0034-72992004000200015
  47. Penido NO, Ramos HVL, Barros FA, Cruz OLM, Toledo RN. Clinical and etiological factors and evolution of hearing in sudden deafness. Braz J Otorhinolaryngol. 2005;71(5):633-638.
  48. Shuknecht HF. Pathology of the Ear. 2nd ed. Philadelphia: Lea & Febiger; 1993.
  49. Bahmad JrF. Temporal bone histopathology — idiopathic sudden hearing loss. Braz J Otorhinolaryngol. 2008;74(1):159.
  50. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: A Challenge in Diagnosis and Treatment. J Audiol Otol. 2018;22(2):59-68. https://doi.org/10.7874/jao.2017.00360
  51. Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Pro- posed comprehensive ototoxicity monitoring program for VA health-care (COMP-VA). J Rehabil Res Dev. 2014;51:81-100. https://doi.org/10.1682/JRRD.2013.04.0092.
  52. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, et al. Amifostine protects against cisplatin-induced oto- toxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008;26:3749-3755.
  53. Riga MG, Chelis L, Kakolyris S, Papadopoulos S, Stathakidou S, Chamalidou E, et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising ef cacy. Am J Clin Oncol. 2013;36:1-6. https://doi.org/10.1097/COC.0b013e31822e006d.
  54. Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, et al. Evaluation of amifostine for protection against cispl- atin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014;16:848-855. https://doi.org/10.1093/neuonc/not241
  55. Dias MA, Sampaio AL, Venosa AR, Meneses Ede A, Oliveira CA. The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study. Int Tinnitus J. 2015;19:12-19. https://doi.org/10.5935/0946-5448.20150003
  56. Feldman L, Efrati S, Eviatar E, Abramsohn R, Yarovoy I, Gersch E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007;72:359-363. https://doi.org/10.1038/sj.ki.5002295
  57. Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493-500.
  58. Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, et al. Children’s Oncology Group. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group study. Cancer. 2005;104:841-847. https://doi.org/10.1002/cncr.21218
  59. Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer. 2009;115:5828-5835. https://doi.org/10.1002/cncr.24667
  60. Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a Randomized Controlled Study. Otolaryngol Head Neck Surg. 2014;150:983-990. https://doi.org/10.1177/0194599814524894
  61. Lilenko SV. Ototoksichnost’ antibiotikov: kak snizit’ riski. Effektivnaya farmakoterapiya. Pul’monologiya i otorinolaringologiya. 2013;1(10):24-28. (In Russ.)
  62. Petrova NN, Perevozchikova VN, Maslova YuA, Perevozchikova NG. Otoprotektivnyy effekt melatonina pri aminoglikozidnoy sensonevral’noy tugoukhosti. Vestnik Sankt-Peterburgskogo universiteta. 2014;11(3):150-157. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.